Key Points
- A/S Genmab bought 120,752 shares on Dec. 16 and 150,795 shares on Dec. 17 of Merus at about $97 per share, spending roughly $26.34 million total and raising its stake to 71,583,829 shares (a 0.17% increase), per an SEC filing.
- Merus shares trade near their 1‑year high (opened $96.80) with a market cap of $7.34 billion and a negative PE, while Wall Street's consensus rating is Hold with an average price target of $93.56.
- Institutional ownership is very high at 96.14%, and several large funds (Wellington, Avoro, Paradigm, Holocene, Westfield) recently increased their positions, signaling concentrated and growing institutional interest.
Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab bought 120,752 shares of Merus stock in a transaction that occurred on Tuesday, December 16th. The stock was purchased at an average cost of $97.00 per share, with a total value of $11,712,944.00. Following the completion of the transaction, the insider owned 71,583,829 shares of the company's stock, valued at $6,943,631,413. This trade represents a 0.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
A/S Genmab also recently made the following trade(s):
- On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $14,627,115.00.
Merus Trading Down 0.1%
Shares of MRUS opened at $96.80 on Friday. The stock has a 50 day simple moving average of $95.61 and a 200-day simple moving average of $75.56. Merus N.V. has a 1 year low of $33.19 and a 1 year high of $96.99. The stock has a market cap of $7.34 billion, a PE ratio of -18.26 and a beta of 1.06.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the stock. Truist Financial cut shares of Merus from a "buy" rating to a "hold" rating and increased their target price for the stock from $88.00 to $97.00 in a research report on Monday, September 29th. Leerink Partnrs cut shares of Merus from a "strong-buy" rating to a "hold" rating in a research note on Sunday, October 5th. Citigroup cut Merus from a "buy" rating to a "neutral" rating and dropped their price target for the company from $101.00 to $97.00 in a report on Monday, September 29th. Canaccord Genuity Group lowered Merus from a "buy" rating to a "hold" rating and boosted their price objective for the stock from $67.00 to $97.00 in a research note on Monday, September 29th. Finally, UBS Group lowered Merus from a "buy" rating to a "neutral" rating and raised their target price for the company from $72.00 to $97.00 in a research note on Tuesday, September 30th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $93.56.
View Our Latest Research Report on MRUS
Institutional Investors Weigh In On Merus
Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in shares of Merus by 34.9% during the first quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock valued at $198,588,000 after acquiring an additional 1,220,519 shares during the period. Avoro Capital Advisors LLC lifted its position in Merus by 12.3% during the 3rd quarter. Avoro Capital Advisors LLC now owns 3,542,500 shares of the biotechnology company's stock valued at $333,526,000 after purchasing an additional 386,945 shares during the period. Paradigm Biocapital Advisors LP boosted its stake in shares of Merus by 99.4% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock valued at $141,831,000 after purchasing an additional 1,679,777 shares during the last quarter. Holocene Advisors LP boosted its stake in shares of Merus by 18.8% in the 2nd quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company's stock valued at $117,048,000 after purchasing an additional 351,616 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its position in shares of Merus by 4.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,132,489 shares of the biotechnology company's stock worth $200,774,000 after buying an additional 90,101 shares during the period. Institutional investors own 96.14% of the company's stock.
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
